These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
447 related articles for article (PubMed ID: 12756078)
21. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women. Jahanzeb M Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537 [TBL] [Abstract][Full Text] [Related]
22. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Sestak I; Cuzick J; Sapunar F; Eastell R; Forbes JF; Bianco AR; Buzdar AU; Lancet Oncol; 2008 Sep; 9(9):866-72. PubMed ID: 18703382 [TBL] [Abstract][Full Text] [Related]
23. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J; Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253 [TBL] [Abstract][Full Text] [Related]
24. Role of anastrozole in adjuvant therapy for postmenopausal patients. Buzdar AU Semin Oncol; 2003 Oct; 30(5 Suppl 16):21-9. PubMed ID: 14613023 [TBL] [Abstract][Full Text] [Related]
25. Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women. Nabholtz JM Am J Hosp Palliat Care; 2004; 21(6):457-65. PubMed ID: 15612238 [TBL] [Abstract][Full Text] [Related]
26. Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer. Michaud LB Am J Health Syst Pharm; 2005 Feb; 62(3):266-73. PubMed ID: 15719584 [TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. Smith IE; Dowsett M; Ebbs SR; Dixon JM; Skene A; Blohmer JU; Ashley SE; Francis S; Boeddinghaus I; Walsh G; J Clin Oncol; 2005 Aug; 23(22):5108-16. PubMed ID: 15998903 [TBL] [Abstract][Full Text] [Related]
28. Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention. Tobias JS Ann Oncol; 2004 Dec; 15(12):1738-47. PubMed ID: 15550578 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. Dowsett M; Cuzick J; Howell A; Jackson I; Br J Cancer; 2001 Aug; 85(3):317-24. PubMed ID: 11487258 [TBL] [Abstract][Full Text] [Related]
30. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. ; Forbes JF; Cuzick J; Buzdar A; Howell A; Tobias JS; Baum M Lancet Oncol; 2008 Jan; 9(1):45-53. PubMed ID: 18083636 [TBL] [Abstract][Full Text] [Related]
31. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach. Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476 [TBL] [Abstract][Full Text] [Related]
32. Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know? Chung CT; Carlson RW Clin Breast Cancer; 2004 Sep; 5 Suppl 1():S18-23. PubMed ID: 15347435 [TBL] [Abstract][Full Text] [Related]
33. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Forbes JF; Sestak I; Howell A; Bonanni B; Bundred N; Levy C; von Minckwitz G; Eiermann W; Neven P; Stierer M; Holcombe C; Coleman RE; Jones L; Ellis I; Cuzick J; Lancet; 2016 Feb; 387(10021):866-73. PubMed ID: 26686313 [TBL] [Abstract][Full Text] [Related]
34. Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study. Aihara T; Takatsuka Y; Ohsumi S; Aogi K; Hozumi Y; Imoto S; Mukai H; Iwata H; Watanabe T; Shimizu C; Nakagami K; Tamura M; Ito T; Masuda N; Ogino N; Hisamatsu K; Mitsuyama S; Abe H; Tanaka S; Yamaguchi T; Ohashi Y Breast Cancer Res Treat; 2010 Jun; 121(2):379-87. PubMed ID: 20390343 [TBL] [Abstract][Full Text] [Related]
35. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955 [TBL] [Abstract][Full Text] [Related]
36. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Boccardo F; Rubagotti A; Guglielmini P; Fini A; Paladini G; Mesiti M; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P Ann Oncol; 2006 Jun; 17 Suppl 7():vii10-4. PubMed ID: 16760270 [TBL] [Abstract][Full Text] [Related]
37. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. Eisen A; Trudeau M; Shelley W; Messersmith H; Pritchard KI Cancer Treat Rev; 2008 Apr; 34(2):157-74. PubMed ID: 18164821 [TBL] [Abstract][Full Text] [Related]
38. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Cuzick J; Sestak I; Baum M; Buzdar A; Howell A; Dowsett M; Forbes JF; Lancet Oncol; 2010 Dec; 11(12):1135-41. PubMed ID: 21087898 [TBL] [Abstract][Full Text] [Related]
39. Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Cella D; Fallowfield L; Barker P; Cuzick J; Locker G; Howell A; Breast Cancer Res Treat; 2006 Dec; 100(3):273-84. PubMed ID: 16944295 [TBL] [Abstract][Full Text] [Related]
40. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Hillner BE Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]